SCHEMBL4665773

SCHEMBL4665773

O=S(=O)(Nc1ccc(Nc2cc(-c3ccc(F)cc3)ncn2)cc1)c1c(F)cccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.56
CYP2C19 P33261 5/20 0.56
CYP2D6 P10635 4/20 0.56
CYP3A4 P08684 4/20 0.56
USP2 O75604 3/20 0.56
CLK4 Q9HAZ1 3/20 0.56
CYP2C9 P11712 2/20 0.56
MAPK1 P28482 2/20 0.56
ALDH1A1 P00352 2/20 0.56
ALOX15 P16050 2/20 0.56
HSD17B10 Q99714 2/20 0.56
MEN1 O00255 1/20 0.56
TP53 P04637 1/20 0.56
GLA P06280 1/20 0.56
KMT2A Q03164 1/20 0.56
ABL1 P00519 9/20 0.51
BCR P11274 9/20 0.51
TSHR P16473 1/20 0.48
HPGD P15428 1/20 0.48
BACE1 P56817 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664293 0.92 CYP1A2 (0.58) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4667528 0.88 ABL1 (0.57) MEN1KMT2AABL1BCRBACE1
SCHEMBL4663875 0.88 CYP1A2 (0.55) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4666116 0.87 ABL1 (0.53) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4666151 0.84 CYP1A2 (0.56) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4667424 0.84 ABL1 (0.58) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4667395 0.83 CYP1A2 (0.46) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4666155 0.81 CYP1A2 (0.48) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4664366 0.81 ABL1 (0.45) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4665707 0.81 CYP1A2 (0.55) CYP1A2CYP2C19CYP2D6CYP3A4USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 CYP1A2 1215/4885CYP2C19 961/4885CYP2D6 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.